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treatment, following the treatment of injuries. Furthermore,
they showed that the accrued cost per life year gained was 
140,750 Euro for malignant neoplasms. This figure is more
than 5 times more cost-effective than treatment for mental
and behavioural disorders and more than 1.5 times more cost-
effective than treatment for respiratory disorders. Among the
various tumour entities, digestive system cancers yielded the
lowest cost-effectiveness, whereas cancers of the lip, mouth
and pharynx were among the most cost-effective treatment
options.
These results are impressive and illustrate the relative merit of
oncological practices. However, some limitations of this
 analysis warrant caution. By design, this type of study may be
subject to considerable confounding factors and may suffer
from the ecologic fallacy. In addition, the findings may be un-
specific, due to poor coding quality and possibly missing data.
In order to clarify the study question, it would be useful to up-
date the results of the study using newer data and to compare
these with the present results. The introduction of new and
more costly treatment options might yield significantly differ-
ent values. Also, it might be useful to contrast these results
with the development of general economic output. 
In summary, Hartmann and co-workers should be applauded
for this neat and crisp analysis. May such analyses help us to
better understand where we are spending our limited re-
sources and in which areas increased spending may be war-
ranted. 
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Undoubtedly, the war on cancer is an expensive endeavour. It
is estimated that, in European countries where data are avail-
able (e.g. Germany and France), cancer care accounts for a
proportion of overall healthcare expenditures similar to that
in the USA, i.e. approximately 5%. Currently, no society can
afford to provide all cancer treatments to all patients that
could benefit from them. How the available resources should
be allocated is one of the great and ongoing debates, and dif-
ferent countries approach this problem in different ways. Ad-
ditionally, the more we understand the pathology, pathogene-
sis, diagnosis, and treatment of cancer, the more options are
created. Many of these options include new diagnostic tools
and more effective treatments. Obviously these innovations,
paired with an increasing number of patients, lead to tremen-
dous health care expenditures, well surpassing current bud-
gets. Hence, the question arises how much money should be
devoted to the management of neoplasms, given that re-
sources are scarce and many other fields and specialities are
competing for these resources. To address this issue it is im-
portant to know which portion of the available funds is allo-
cated to oncological care and how efficiently this care is pro-
vided.
Hartmann and colleagues elegantly strive to give an answer to
this question by analysing oncological resources and their effi-
ciency [1]. They developed a very simple and transparent
model using a macroeconomic perspective. On the basis of
publicly available, official data sources they calculated
oncology- related expenditures and contrasted these with the
number of years of life gained between the years 2002 and
2004 in Germany. They were able to give estimates related to
different disease categories and different malignancies. For ex-
ample, they were able to demonstrate that the second largest
contributors of life years gained were based on oncological
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